Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

109.86 +2.92 (+2.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Technical Analysis observations. ↗

March 06, 2025

Exploring HALOZYME THERAPEUTICS INC's Technical Signals and Breakout Potential: A technical analysis of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows it may be setting up for a breakout.

Via Chartmill

NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗

February 26, 2025

Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts ↗

February 20, 2025

Via Benzinga

NASDAQ:HALO is not too expensive for the growth it is showing. ↗

February 17, 2025

HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

Via Chartmill

NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. ↗

February 17, 2025

Discover HALOZYME THERAPEUTICS INC, an undervalued stock. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why. ↗

February 03, 2025

A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.

Via Chartmill

Analyst Expectations For Halozyme Therapeutics's Future ↗

January 13, 2025

Via Benzinga

9 Analysts Have This To Say About Halozyme Therapeutics ↗

December 18, 2024

Via Benzinga

Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock? ↗

December 18, 2024

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Earnings Scheduled For February 18, 2025 ↗

February 18, 2025

Via Benzinga

Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews ↗

February 04, 2025

Via Benzinga

Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗

December 16, 2024

NASDAQ:HALO, a growth stock which is not overvalued.

Via Chartmill

NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

February 03, 2025

Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.

Via Chartmill

In the world of growth stocks, NASDAQ:HALO shines as a value proposition. ↗

January 27, 2025

HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗

January 24, 2025

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

BeiGene Stock Meets 80-Plus RS Rating Benchmark ↗

January 15, 2025

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.

Via Investor's Business Daily

BridgeBio Pharma Stock Earns 87 RS Rating ↗

January 14, 2025

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

Via Investor's Business Daily

SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗

January 08, 2025

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

Via Investor's Business Daily

(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗

December 11, 2024

Via Benzinga

Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views ↗

November 20, 2024

Via Benzinga

Looking Into Halozyme Therapeutics's Recent Short Interest ↗

November 05, 2024

Via Benzinga

Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗

January 06, 2025

Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗

January 03, 2025

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

Via Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗

December 13, 2024

For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.

Via Chartmill

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook ↗

November 22, 2024

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.

Via Benzinga

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗

November 22, 2024

NASDAQ:HALO stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

November 22, 2024

Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued.

Via Chartmill

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion ↗

November 15, 2024

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.

Via Benzinga

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday ↗

November 01, 2024

Via Benzinga

Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗

November 01, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.